GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Total Liabilities

Affimed NV (Affimed NV) Total Liabilities

: $42.91 Mil (As of Dec. 2023)
View and export this data going back to 2014. Start your Free Trial

Affimed NV's Total Liabilities for the quarter that ended in Dec. 2023 was $42.91 Mil.

Affimed NV's quarterly Total Liabilities increased from Jun. 2023 ($38.77 Mil) to Sep. 2023 ($47.01 Mil) but then declined from Sep. 2023 ($47.01 Mil) to Dec. 2023 ($42.91 Mil).

Affimed NV's annual Total Liabilities declined from Dec. 2021 ($100.77 Mil) to Dec. 2022 ($50.42 Mil) and declined from Dec. 2022 ($50.42 Mil) to Dec. 2023 ($42.91 Mil).


Affimed NV Total Liabilities Historical Data

The historical data trend for Affimed NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Liabilities
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.88 126.20 100.77 50.42 42.91

Affimed NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Liabilities Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.42 45.90 38.77 47.01 42.91

Affimed NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Affimed NV's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=28.252+(14.154+2.2204460492503E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.506+0)
=42.91

Total Liabilities=Total Assets (A: Dec. 2023 )-Total Equity (A: Dec. 2023 )
=105.951-63.039
=42.91

Affimed NV's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=28.252+(14.154+2.2204460492503E-16
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0.506+0)
=42.91

Total Liabilities=Total Assets (Q: Dec. 2023 )-Total Equity (Q: Dec. 2023 )
=105.951-63.039
=42.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Affimed NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of Affimed NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Affimed NV (Affimed NV) Business Description

Traded in Other Exchanges
Address
Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120
Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.

Affimed NV (Affimed NV) Headlines

From GuruFocus

Affimed Reports on Corporate Progress and Provides Regulatory Update for AFM13

By Stock market mentor Stock market mentor 01-09-2023